Relay Therapeutics (RLAY) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

RLAY Stock Forecast

Relay Therapeutics stock forecast is as follows: an average price target of $19.40 (represents a 316.31% upside from RLAY’s last price of $4.66) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

RLAY Price Target

The average price target for Relay Therapeutics (RLAY) is $19.40 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $16.00. This represents a potential 316.31% upside from RLAY's last price of $4.66.

RLAY Analyst Ratings

Buy

According to 9 Wall Street analysts, Relay Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for RLAY stock is 1 'Strong Buy' (11.11%), 7 'Buy' (77.78%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Relay Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 16, 2024	Robert Burns	H.C. Wainwright	$19.00	$7.60	150.00%	307.73%
Sep 10, 2024	Akash Tewari	Jefferies	$16.00	$9.51	68.24%	243.35%
Sep 09, 2024	Peter Lawson	Barclays	$17.00	$9.51	78.76%	264.81%
Sep 04, 2024	Jason Gerberry	Bank of America Securities	$20.00	$6.41	212.01%	329.18%
May 10, 2024	Peter Lawson	Barclays	$15.00	$6.68	124.66%	221.89%
May 06, 2024	Matt Biegler	Oppenheimer	$25.00	$7.04	255.11%	436.48%
Apr 20, 2023	Akash Tewari	Jefferies	$12.50	$12.35	1.21%	168.24%
Feb 03, 2023	-	Oppenheimer	$33.00	$22.76	44.99%	608.15%
Sep 30, 2022	Peter Lawson	Barclays	$23.00	$23.14	-0.61%	393.56%

Row per page

Go to

The latest Relay Therapeutics stock forecast, released on Sep 16, 2024 by Robert Burns from H.C. Wainwright, set a price target of $19.00, which represents a 150.00% increase from the stock price at the time of the forecast ($7.60), and a 307.73% increase from RLAY last price ($4.66).

Relay Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	4	6
Avg Price Target	-	$18.00	$18.67
Last Closing Price	$4.66	$4.66	$4.66
Upside/Downside	-100.00%	286.27%	300.64%

In the current month, the average price target of Relay Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Relay Therapeutics's last price of $4.66. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 14, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 16, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 09, 2024	Oppenheimer	Buy	Perform	Downgrade
Sep 09, 2024	Barclays	Overweight	Overweight	Hold
Sep 04, 2024	Bank of America Securities	Buy	Buy	Hold
Aug 07, 2024	Oppenheimer	Buy	Buy	Hold
Aug 07, 2024	JMP Securities	Underperform	Underperform	Hold
Jul 17, 2024	JMP Securities	Underperform	Underperform	Hold
Jul 17, 2024	Oppenheimer	Market Outperform	Market Outperform	Hold
Jun 07, 2024	Cowen & Co.	Buy	Buy	Hold

Row per page

Go to

Relay Therapeutics's last stock rating was published by H.C. Wainwright on Oct 14, 2024. The company gave RLAY a "Buy" rating, the same as its previous rate.

Relay Therapeutics Financial Forecast

Relay Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
Revenue	-	-	-	-	-	-	-	-	-	$25.20M	$119.00K	$226.00K	$253.00K	$344.00K	$365.00K	$419.00K	$567.00K	$666.00K	$844.00K	$952.00K	$82.65M
Avg Forecast	$40.00K	$33.33K	$50.00K	$50.00K	$88.89K	$88.89K	$88.89K	$120.00K	$581.82K	$374.55K	$741.67K	$128.00K	$271.43K	$1.80M	$2.08M	$166.67K	$3.84M	$107.14K	$6.67M	$3.39M	$36.67M
High Forecast	$50.91K	$42.42K	$63.64K	$63.64K	$126.98K	$88.94K	$88.94K	$121.50K	$1.08M	$377.04K	$943.94K	$162.91K	$345.45K	$1.80M	$2.08M	$166.67K	$3.84M	$107.14K	$6.67M	$3.39M	$36.67M
Low Forecast	$29.09K	$24.24K	$36.36K	$36.36K	$50.79K	$88.83K	$88.83K	$118.50K	$215.49K	$372.05K	$539.39K	$93.09K	$197.40K	$1.80M	$2.08M	$166.67K	$3.84M	$107.14K	$6.67M	$3.39M	$36.67M
# Analysts	1	1	1	3	5	4	1	1	3	12	9	9	5	5	5	5	6	6	6	6	9
Surprise %	-	-	-	-	-	-	-	-	-	67.29%	0.16%	1.77%	0.93%	0.19%	0.18%	2.51%	0.15%	6.22%	0.13%	0.28%	2.25%

Relay Therapeutics's average Quarter revenue forecast for Dec 23 based on 3 analysts is $581.82K, with a low forecast of $215.49K, and a high forecast of $1.08M. RLAY's average Quarter revenue forecast represents a -97.69% decrease compared to the company's last Quarter revenue of $25.20M (Sep 23).

Relay Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	3	5	4	1	1	3	12	9	9	5	5	5	5	6	6	6	6	9
EBITDA	-	-	-	-	-	-	-	-	-	$-73.58M	$-106.05M	$-101.18M	$-93.94M	$-78.33M	$-76.45M	$-70.94M	$-66.42M	$-59.82M	$-192.44M	$-41.27M	$36.19M
Avg Forecast	$-21.06K	$-17.55K	$-26.32K	$-26.32K	$-46.79K	$-46.79K	$-46.79K	$-57.04M	$-306.28K	$-197.17K	$-390.43K	$-61.00M	$-57.82M	$-947.56K	$-1.10M	$-65.24M	$-2.02M	$-56.40K	$-3.51M	$-42.12M	$-19.30M
High Forecast	$-15.31K	$-12.76K	$-19.14K	$-19.14K	$-26.74K	$-46.76K	$-46.76K	$-45.63M	$-113.44K	$-195.85K	$-283.95K	$-48.80M	$-46.26M	$-947.56K	$-1.10M	$-52.20M	$-2.02M	$-56.40K	$-3.51M	$-33.70M	$-19.30M
Low Forecast	$-26.80K	$-22.33K	$-33.50K	$-33.50K	$-66.85K	$-46.82K	$-46.82K	$-68.45M	$-567.19K	$-198.48K	$-496.91K	$-73.20M	$-69.39M	$-947.56K	$-1.10M	$-78.29M	$-2.02M	$-56.40K	$-3.51M	$-50.55M	$-19.30M
Surprise %	-	-	-	-	-	-	-	-	-	373.17%	271.62%	1.66%	1.62%	82.67%	69.71%	1.09%	32.86%	1060.62%	54.83%	0.98%	-1.87%

6 analysts predict RLAY's average Quarter EBITDA for Mar 21 to be $-42.12M, with a high of $-33.70M and a low of $-50.55M. This is -216.41% lower than Relay Therapeutics's previous annual EBITDA (Dec 20) of $36.19M.

Relay Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	3	5	4	1	1	3	12	9	9	5	5	5	5	6	6	6	6	9
Net Income	-	-	-	-	-	-	-	-	-	$-65.73M	$-98.50M	$-87.30M	$-43.31M	$-87.26M	$-75.16M	$-51.48M	$-67.46M	$-60.83M	$-193.40M	$-42.18M	$35.28M
Avg Forecast	$-90.21M	$-89.15M	$-86.94M	$-83.94M	$-85.19M	$-108.24M	$-102.75M	$-58.62M	$-100.71M	$-115.69M	$-114.35M	$-62.69M	$-58.72M	$-93.71M	$-83.30M	$-67.05M	$-74.24M	$-81.29M	$-59.58M	$-43.06M	$22.36M
High Forecast	$-58.23M	$-57.54M	$-56.12M	$-73.11M	$-70.55M	$-69.87M	$-66.32M	$-46.89M	$-92.76M	$-93.39M	$-73.81M	$-50.15M	$-46.98M	$-93.71M	$-83.30M	$-53.64M	$-74.24M	$-81.29M	$-59.58M	$-34.45M	$22.36M
Low Forecast	$-122.20M	$-120.75M	$-117.77M	$-94.77M	$-98.50M	$-146.62M	$-139.18M	$-70.34M	$-104.68M	$-125.45M	$-154.89M	$-75.23M	$-70.47M	$-93.71M	$-83.30M	$-80.46M	$-74.24M	$-81.29M	$-59.58M	$-51.68M	$22.36M
Surprise %	-	-	-	-	-	-	-	-	-	0.57%	0.86%	1.39%	0.74%	0.93%	0.90%	0.77%	0.91%	0.75%	3.25%	0.98%	1.58%

Relay Therapeutics's average Quarter net income forecast for Mar 21 is $-43.06M, with a range of $-51.68M to $-34.45M. RLAY's average Quarter net income forecast represents a -222.07% decrease compared to the company's last Quarter net income of $35.28M (Dec 20).

Relay Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	3	5	4	1	1	3	12	9	9	5	5	5	5	6	6	6	6	9
SG&A	-	-	-	-	-	-	-	-	-	$18.48M	$20.12M	$19.58M	$16.37M	$16.07M	$17.46M	$16.07M	$15.55M	$14.68M	$14.42M	$12.73M	$15.54M
Avg Forecast	$568.97K	$474.14K	$711.22K	$711.22K	$1.26M	$1.26M	$1.26M	$1.71M	$8.28M	$5.33M	$10.55M	$1.82M	$3.86M	$25.60M	$29.63M	$2.37M	$54.62M	$1.52M	$94.83M	$48.23M	$521.56M
High Forecast	$724.15K	$603.44K	$905.18K	$905.18K	$1.81M	$1.27M	$1.27M	$1.73M	$15.33M	$5.36M	$13.43M	$2.32M	$4.91M	$25.60M	$29.63M	$2.37M	$54.62M	$1.52M	$94.83M	$48.23M	$521.56M
Low Forecast	$413.79K	$344.83K	$517.24K	$517.24K	$722.50K	$1.26M	$1.26M	$1.69M	$3.07M	$5.29M	$7.67M	$1.32M	$2.81M	$25.60M	$29.63M	$2.37M	$54.62M	$1.52M	$94.83M	$48.23M	$521.56M
Surprise %	-	-	-	-	-	-	-	-	-	3.47%	1.91%	10.75%	4.24%	0.63%	0.59%	6.78%	0.28%	9.63%	0.15%	0.26%	0.03%

Relay Therapeutics's average Quarter SG&A projection for Dec 23 is $8.28M, based on 3 Wall Street analysts, with a range of $3.07M to $15.33M. The forecast indicates a -55.23% fall compared to RLAY last annual SG&A of $18.48M (Sep 23).

Relay Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20
# Analysts	1	1	1	3	5	4	1	1	3	12	9	9	5	5	5	5	6	6	6	6	9
EPS	-	-	-	-	-	-	-	-	-	$-0.00	$-0.00	$-0.72	$-0.36	$-0.79	$-0.69	$-0.48	$-0.66	$-0.66	$-2.10	$-0.47	$0.50
Avg Forecast	$-0.64	$-0.64	$-0.62	$-0.60	$-0.61	$-0.77	$-0.73	$-0.73	$-0.72	$-0.82	$-0.82	$-0.69	$-0.70	$-0.71	$-0.63	$-0.62	$-0.56	$-0.61	$-0.45	$-0.49	$0.17
High Forecast	$-0.42	$-0.41	$-0.40	$-0.52	$-0.50	$-0.50	$-0.47	$-0.47	$-0.66	$-0.67	$-0.53	$-0.45	$-0.45	$-0.71	$-0.63	$-0.62	$-0.56	$-0.61	$-0.45	$-0.49	$0.17
Low Forecast	$-0.87	$-0.86	$-0.84	$-0.68	$-0.70	$-1.05	$-0.99	$-0.98	$-0.75	$-0.89	$-1.10	$-0.94	$-0.95	$-0.71	$-0.63	$-0.62	$-0.56	$-0.61	$-0.45	$-0.49	$0.17
Surprise %	-	-	-	-	-	-	-	-	-	0.00%	0.00%	1.04%	0.51%	1.12%	1.10%	0.78%	1.18%	1.08%	4.68%	0.97%	2.94%

According to 6 Wall Street analysts, Relay Therapeutics's projected average Quarter EPS for Mar 21 is $-0.49, with a low estimate of $-0.49 and a high estimate of $-0.49. This represents a -198.10% decrease compared to RLAY previous annual EPS of $0.50 (Dec 20).

Relay Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
IPSC	Century Therapeutics	$1.26	$15.00	1090.48%	Buy
BDTX	Black Diamond Therapeutics	$2.43	$14.75	507.00%	Buy
LIFE	aTyr Pharma	$1.90	$11.00	478.95%	Buy
RLAY	Relay Therapeutics	$4.66	$19.40	316.31%	Buy
CCCC	C4 Therapeutics	$4.05	$13.50	233.33%	Buy
ARVN	Arvinas	$22.69	$71.00	212.91%	Buy
PLRX	Pliant Therapeutics	$12.73	$39.71	211.94%	Buy
DAWN	Day One Biopharmaceuticals	$13.62	$38.80	184.88%	Buy
APLS	Apellis Pharmaceuticals	$27.49	$74.50	171.01%	Buy
STOK	Stoke Therapeutics	$11.31	$30.60	170.56%	Buy
TERN	Terns Pharmaceuticals	$5.60	$14.25	154.46%	Buy
CGEM	Cullinan Oncology	$12.58	$31.50	150.40%	Buy
MLYS	Mineralys Therapeutics	$12.60	$30.00	138.10%	Buy
FHTX	Foghorn Therapeutics	$7.86	$16.33	107.76%	Buy
NRIX	Nurix Therapeutics	$22.64	$32.20	42.23%	Buy
EWTX	Edgewise Therapeutics	$31.95	$45.00	40.85%	Buy
AMLX	Amylyx Pharmaceuticals	$5.23	$6.67	27.53%	Buy
BPMC	Blueprint Medicines	$94.81	$109.71	15.72%	Buy

RLAY Forecast FAQ

Is Relay Therapeutics a good buy?

Yes, according to 9 Wall Street analysts, Relay Therapeutics (RLAY) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 7 'Buy' recommendations, accounting for 88.89% of RLAY's total ratings.

What is RLAY's price target?

Relay Therapeutics (RLAY) average price target is $19.4 with a range of $16 to $25, implying a 316.31% from its last price of $4.66. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Relay Therapeutics stock go up soon?

According to Wall Street analysts' prediction for RLAY stock, the company can go up by 316.31% (from the last price of $4.66 to the average price target of $19.4), up by 436.48% based on the highest stock price target, and up by 243.35% based on the lowest stock price target.

Can Relay Therapeutics stock reach $7?

RLAY's average twelve months analyst stock price target of $19.4 supports the claim that Relay Therapeutics can reach $7 in the near future.

What are Relay Therapeutics's analysts' financial forecasts?

Relay Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $386.67K (high $426.37K, low $346.96K), average EBITDA is $-57.178M (high $-45.751M, low $-68.606M), average net income is $-355M (high $-254M, low $-455M), average SG&A $5.5M (high $6.06M, low $4.94M), and average EPS is $-2.839 (high $-1.943, low $-3.725). RLAY's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $173.33K (high $220.6K, low $126.06K), average EBITDA is $-91.245K (high $-66.358K, low $-116K), average net income is $-350M (high $-245M, low $-455M), average SG&A $2.47M (high $3.14M, low $1.79M), and average EPS is $-2.498 (high $-1.747, low $-3.248).

Did the RLAY's actual financial results beat the analysts' financial forecasts?

Based on Relay Therapeutics's last annual report (Dec 2022), the company's revenue was $1.38M, which missed the average analysts forecast of $4.32M by -68.04%. Apple's EBITDA was $-323M, beating the average prediction of $-125M by 157.88%. The company's net income was $-254M, missing the average estimation of $-303M by -16.03%. Apple's SG&A was $65.98M, beating the average forecast of $61.47M by 7.33%. Lastly, the company's EPS was $-2.27, missing the average prediction of $-2.653 by -14.44%. In terms of the last quarterly report (Sep 2023), Relay Therapeutics's revenue was $25.2M, beating the average analysts' forecast of $374.54K by 6628.70%. The company's EBITDA was $-73.577M, beating the average prediction of $-197K by 37216.72%. Relay Therapeutics's net income was $-65.734M, missing the average estimation of $-116M by -43.18%. The company's SG&A was $18.48M, beating the average forecast of $5.33M by 246.96%. Lastly, the company's EPS was $-0.0005, missing the average prediction of $-0.825 by -99.94%